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Conclusion and Clinical Relevance: Our	results	showed	that	the	FCER2	T2206C	vari‐
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asthma,	FCER2	T2206C	variant,	fractional	exhaled	nitric	oxide,	inhaled	corticosteroid









fragment	 of	 the	 IgE	 receptor	 II	 (FCER2)	 gene	which	 is	 an	 11‐exon	
gene	 located	 at	 chromosome	 19p13.2.	 Variants	 of	 FCER2 could 
modify	 the	 IgE	synthesis.7	Furthermore,	 in	asthmatic	patients,	 the	
rs28364072	polymorphism	(T2206C)	in	FCER2	has	previously	been	




results	 from	oxidation	of	 l‐arginine	 in	 the	presence	of	nitric	oxide	
synthase	(NOS).	Three	different	isoforms	of	NOS	exist:	two	consti‐
tutive	NOS	(cNOS)	isoforms	and	one	inducible	NOS	(iNOS)	isoform.	



















this	 association	 in	 asthmatic	 children	 being	 treated	 with	 asthma	
medication.




2.1 | Study setting and population
The	 study	 was	 undertaken	 in	 the	 PACMAN	 (Pharmacogenetics	
of	 Asthma	medication	 in	 Children:	Medication	 with	 Anti‐inflam‐
matory	effects)	 cohort	 study.	Details	of	 the	 study	protocol	have	
been	described	elsewhere.21	In	short,	the	PACMAN	study	includes	
children	 (aged	 4‐12	 years)	 who	 were	 selected	 through	 pharma‐
cies	 that	 belonged	 to	 the	 Utrecht	 Pharmacy	 Practice	 Network	
for	 Education	 and	 Research	 (UPPER).22	 Children	 who	 regularly	
used	asthma	medication	 (Anatomical	Therapeutic	Chemical	 code	
R03),	 namely	 ≥3	 prescriptions	 within	 the	 last	 2	 years	 and	 ≥1	
prescription(s)	 in	the	last	6	months,	were	recruited	through	com‐







measured	 (NIOX	Mino;	 Aerocrine),	 and	 saliva	 samples	were	 col‐
lected	for	DNA	extraction	(Oragene	DNA	Self‐Collection	kit;	DNA	
Genotek,	 Inc.,	Kanata,	ON,	Canada).	 In	 the	PACMAN	study,	daily	
ICS	dosages	(defined	daily	dosages	of	budesonide	equivalent)	were	
based	on	the	last	recorded	refill	prescription	in	the	pharmacy	prior	
to	 the	 study	 visit.	 The	 parents	 provided	 written	 informed	 con‐
sent,	and	the	PACMAN	cohort	study	was	approved	by	the	Medical	
Ethics	Committee	of	 the	University	Medical	Centre	Utrecht.	The	
study	 population	 for	 our	 analysis	 consisted	 of	 all	 asthmatic	 chil‐
dren	 treated	with	 inhaled	corticosteroids	 (ICS)	and	who	also	had	
FENO	measurements,	genotyping	and	questionnaire	data.
2.2 | Definition of fraction of nitric oxide in 
exhaled breath















Potential	 confounders/covariates	 consisted	 of	 age,	 sex,	 (adapted)	
British	 Thoracic	 Society	 guidelines28	 treatment	 steps	 (BTS)	 and	
atopy.	We	defined	treatment	step	as	follows:	step	0,	no	use	of	inhaled	
short‐acting	 β2‐agonist;	 step	 1,	 short‐acting	 β2‐agonist	 as	 needed;	
step	2,	step	1	plus	regular	ICS;	step	3,	step	2	plus	long‐acting	β2‐ago‐
nist;	step	4,	step	3	plus	oral	 leukotriene	receptor	antagonist.	Since	





of	 the	6‐item	version	of	 the	Asthma	Control	Questionnaire	 (ACQ)	
(investigates	 respiratory	 symptoms	 and	 need	 of	 short‐acting	 β2‐
agonists).29	 A	mean	 score	 of	 ACQ	≥	 0.75	 indicated	 ‘not	well‐con‐
trolled	asthma’	and	an	ACQ	score	of	<0.75	indicated	‘well‐controlled	
asthma’.23,30
2.5 | Functional annotation of SNPs in strong LD 
with rs28364072
We	 retrieved	 all	 proxy	 SNPs	 in	 high	 linkage	 disequilibrium	 (LD)	
(R2	 >	 0.8,	 limit	 distance	 100	 kb,	 and	 population	 panel	 CEU	 using	




2.6 | Expression quantitative trait loci analysis
The	correlation	of	 the	SNP	 rs28364072	and	 its	proxies	 in	high	LD	
with	the	expression	level	of	FCER2	gene	in	whole	blood	was	checked	
(expression	quantitative	trait	loci	[eQTL]	analysis)	using	publicly	avail‐
able	 data	 from	 (GTEx)	 portal	 (GTEx	 portal:www.gtexp	ortal.org/













Kruskal‐Wallis	 test	was	used	 to	assess	whether	 there	was	a	sta‐
tistically	significant	difference	 in	the	concentration	of	FENO	be‐
tween	 three	 genotype	 categories	 of	 FCER2	 rs28364072	 namely	








used	 to	 evaluate	 whether	 there	 was	 a	 significant	 difference	 in	









assess	whether	 there	was	 a	 statistically	 significant	 difference	 in	
the	median	 FENO	 level	 between	 patients	 treated	with	 low,	me‐
dium	and	high	ICS	dosages.
An	 additive	 genetic	 model	 was	 assumed,	 and	 the	 association	
between	 the	 FCER2	 T2206C	 variant	 and	 FENO	 concentrations	
was	 assessed	 using	 linear	 regression.	As	 FENO	was	 not	 normally	
distributed,	 FENO	 levels	 were	 used	 as	 log‐transformed,	 natural	

















urements	 and	 FCER2	 genotype	 information	 was	 available	 within	





with	 an	 interquartile	 range	 (IOR)	 of	 8.0‐27.5	 ppb.	 The	 median	
value	 of	 FENO	was	 significantly	 lower	 in	well‐controlled	 asthma	






population	 (P	 =	0.051),	 in	 the	category	of	well‐controlled	asthma	
(P	 =	 0.121)	 and	 in	 the	 category	 of	 not	 well‐controlled	 asthma	
(P	=	0.219).
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for	multiple	 testing,	 the	FENO	 levels	 remained	significantly	differ‐











3.2 | Association of FCER2 variant with FENO levels







TA B L E  1  Characteristics	of	study	population




(ACQ ≥ 0.75) Pa
n 593 341/581b 240/581b  
Age,	mean	(±	SD) 9.1	±	2.2 9.0	±	2.1 9.2	±	2.2  
Male,	%	(n) 62.1	(368) 62.8	(127) 61.7	(148) 0.795
History	of	atopyc	%	(n) 82	(484/590) 82.4	(280/340) 82.5	(198/240) 0.963
Eczemac,	%	(n) 66.9	(394/589) 65.9	(224/340) 69.9	(167/239) 0.313
Food	allergyc,	%	(n) 52.1	(306/587) 48.4 (164/339) 58.0 (138/238) 0.023
Hayfeverc,	%	(n) 46.4	(269/580) 45.4	(152/335) 48.5	(114/235) 0.460
Family history of atopy
Paternal	asthmac	%	(n) 29.9	(163/546) 27.8	(88/317) 32.9	(72/219) 0.203
Paternal	eczemac	%	(n) 27.6	(147/533) 28.0	(87/311) 27.7	(59/213) 0.945
Paternal	hayfeverc	%	(n) 38.2	(206/539 38.1	(119/312) 39.2	(85/217) 0.811
Maternal	asthmac	%	(n) 26.6	(147/553) 21.1 (66/313) 33.2 (76/229) 0.002
Maternal	eczemac	%	(n) 39.9	(222/556) 36.5	(116/318) 44.1	(100/227) 0.075
Maternal	hayfeverc	%	(n) 44.3	(247/557) 43.2	(137/317) 46.3	(106/229) 0.476
Adapted BTS treatment stepd % (n)
2 69.1	(410) 74.7 (248) 66.8 (155) 0.012
3 20.9	(124) 20.8 (69) 22.4 (52)
4 6.9	(41) 4.5 (15) 10.8 (25)
Minor	allele	frequency	FCER2	variant	% 29.6 29.5 29.9 0.982
Genotype distribution T2206C variant
Homozygous	wild‐type	(AA)	%	(n) 51.4	(305) 51.6	(176) 50.8	(122)
Heterozygous	(AG)	%	(n) 38.1	(226) 37.8	(129) 38.3	(92)
Homozygous	variant	(GG)	%	(n) 10.5	(62) 10.6	(36) 10.8	(26)
FENO	ppb,	median	(IQR) 13.0	(8.0‐27.5) 13.0 (8.0‐25.0) 16.0 (9.0‐31.8) 0.044
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3.3 | Association of FCER2 variant with FENO levels 
stratified by ACQ scores
We	 tested	 the	 association	 between	 the	 variant	 and	 FENO	 levels	













3.4 | Correlation of FENO levels and ICS 
daily dosage
Data	 on	 ICS	 dosage	 were	 available	 for	 475	 out	 of	 593	 subjects.	
There	 was	 no	 correlation	 between	 FENO	 levels	 and	 ICS	 dosage	
(Spearman's	 rank	correlation	coefficient	 [RS]	=	−0.016,	P	=	0.736).	
When	subjects	were	grouped	according	to	defined	daily	ICS	dosage	
(low,	medium,	 high),	 higher	FENO	 levels	 could	be	observed	 in	 the	
patients	 treated	with	 low	dosages	of	 ICS	category	 (median	FENO:	
17.0ppb	[IQR:	8.0‐30.0])	compared	to	patients	treated	with	medium	
ICS	 dosages	 (median	 FENO:	 14.00	 ppb	 [IQR:	 8.0‐23.0])	 and	 high	
ICS	dosages	(median	FENO:	11.5	ppb	[IQR:	7.0‐25.7]);	however,	the	
differences	were	not	statistically	significant.	In	addition,	there	was	
no	significant	correlation	between	FENO	 levels	and	 ICS	dosage	 in	
carriers	 or	 non‐carries	 of	 the	FCER2	 T2206C	variant	 (RS	=	0.025,	
P	=	0.703	and	RS	=	−0.038,	P	=	0.554,	respectively).
3.5 | Functional annotation and eQTL 
analysis of rs28364072
Functional	 annotation,	 using	 Haploreg	 v4.1	 data,	 shows	 that	
rs28364072	has	several	proxy	variants	(D′	=	1	and	R2	>	0.8),	but	they	
are	all	 intronic	 and	 synonymous,	without	 any	predicted	 functions,	
rs28364072 Genotypes FENOappb (IQR)
Pairwise comparison of 
FENO levels Pb
Total population (n = 593)
Homozygous	variant	(GG) 10.0	(7.0‐22.2) GG‐AG 0.541
Heterozygous	(AG) 12.0	(7.0‐27.2) GG‐AA 0.029
Homozygous	wild‐type	(AA) 16.0	(9.0‐28.5) AG‐AA 0.014
Well‐controlled (n = 341)a
Homozygous	variant	(GG) 10.0	(7.0‐20.8) GG‐AG 0.526
Heterozygous	(AG) 12.0	(7.0‐23.0) GG‐AA 0.041
Homozygous	wild‐type	(AA) 14.5	(8.0‐28.8) AG‐AA 0.029
Not well‐controlled (n = 240)a









TA B L E  2  Concentration	of	FENO	
among	genotypes	of	rs28364072
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(Table	 S3).	 Moreover,	 the	 cis‐eQTL	 data	 from	 GTEx	 portal	 and	
GeneNetwork31	 showed	 that	 the	minor	 allele	G	of	 rs28364072	 is	
significantly	 associated	 with	 reduced	 expression	 levels	 of	 FCER2 












To	 the	best	of	our	knowledge,	 the	current	study	 is	 the	 first	 to	
evaluate	 the	 association	 between	 the	 FCER2	 T2206C	 variant	 and	








not	 on	medication	 for	 at	 least	 one	month	 before	 inclusion,	 while	
in	the	PACMAN	study	all	subjects	were	on	 ICS	treatment	and	 ICS	
therapy	 is	 known	 to	decrease	FENO	 levels.34	 In	 addition,	 the	 fre‐
quency	of	the	rs28364072	homozygous	variant	of	the	FCER2	gene	
was	slightly	higher	among	Vietnamese	children	(15.6%)	than	(10.5%)	





receptor,	 CD23,	 by	 nature	 inhibits	 IgE	 production.6 The FCER2 
gene	 affects	 the	 inflammatory	 mechanisms	 and	 results	 in	 the	
variability	 in	 the	 response	 to	 ICS	 in	asthma.35	The	T2206C	vari‐
ant	 is	 located	 in	 splicing	 region	 of	 intron	 9	 of	 FCER2	 and	might	
lead	 to	 alternative	 splicing	 and	 changes	 of	 the	 gene	 transcript	
length.	Tantisira	et	al	showed	that	the	T2206C	variant	was	asso‐
ciated	with	lower	FCER2	gene	expression.9	This	was	suggested	to	
be	 a	 possible	 mechanism	 for	 the	 higher	 IgE	 levels	 among	 carri‐
ers	of	the	mutant	(C)	allele	in	their	findings.9	In	animal	models,	it	
was	 confirmed	 that	 absence	 of	 CD23	 (CD23‐/‐)	 in	 the	 knockout	
mice	 resulted	 in	 elevated	 IgE‐mediated	 response	 compared	with	
TA B L E  3  Concentration	of	FENO	between	carries	and	non‐
carriers	of	the	G	allele	of	rs28364072
rs28364072 variation n
FENO ppb median 
(IQR) Pa


























TA B L E  4  Regression	coefficients	and	95%	confidence	intervals	describing	the	association	between	rs28364072	variation	of	the	FCER2 
gene	(per	copy	of	the	G	allele)	and	the	concentration	of	FENO
Crude Model 1 Model 2
FENOa Effect allele β (95% CI) P‐value  β (95% CI) P‐value β (95% CI) P‐value
Total	population	
(n	=	593)
G −0.15 (−0.26, −0.05) 0.005 −0.12 (−0.22, −0.02) 0.021 −0.12 (−0.23, −0.02) 0.018
Well‐controlleda 
(n	=	341)
G −0.18 (−0.32, −0.05) 0.007 −0.16 (−0.29, −0.03) 0.019 −0.17 (−0.30, −0.04) 0.011
Not	well‐con‐
trolleda	(n	=	240)





















among	 carriers	 of	 the	 variant;	 hence,	 the	observed	 lower	FENO	
levels	in	carriers	of	the	FCER2	T2206C	variant	is	plausible.
It	 should	be	noted	 that	children	 in	our	study	with	not	well‐con‐
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